

# BACIL PHARMA LIMITED

Reg Office: G2 & G3 Samarpan Complex, Next to Mirador Hotel, Chakala, Andheri East, Mumbai - 400099  
Email Id: bacilpha@yahoo.com, CIN: L24200MH1987PLC043427, Tel: 22618452/22661541, Tel/Fax: 22618327

---

Date: 13.02.2026

To,  
Gen. Manager (DCS)  
BSE Limited.  
P J Towers, Dalal Street,  
Fort, Mumbai-400001

**Scrip Code: 524516**

**Scrip Id: BACPHAR**

Sub: Outcome of the Board Meeting held on Friday, 13<sup>th</sup> February, 2026

Ref: Regulation 30 & 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir/Madam,

Pursuant to Regulation 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI LODR Regulations"), we wish to inform you that the Meeting of the Board of Directors of Bacil Pharma Limited was held on Friday, 13<sup>th</sup> February, 2026 at the Registered Office of the Company, wherein the Board has, inter alia, considered and approved the following:

1. Approved the Unaudited Financial Results of the Company for the quarter and Nine Month ended December 31, 2025, along with the Limited Review Report issued by the Statutory Auditors of the Company.

The meeting of the Board of Directors commenced at 01:00P.M. and concluded at 02:00 P.M.

The Unaudited Financial Results and Limited Review Report will be submitted separately in the prescribed format as per SEBI LODR Regulations.

Kindly take the above on your record and acknowledge the receipt.

Thanking you,.

Sincerely,

**For Bacil Pharma Limited**

Shah Chaitali  
Kalpataru

Digitally signed by  
Shah Chaitali Kalpataru  
Date: 2026.02.13  
14:11:38 +05'30'

**Ms. Chaitali Kalpataru Shah**

**Director & CFO**

**DIN: 11167778**

# BACIL PHARMA LIMITED

{CIN : L24200MH1987PLC043427}

## UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER/NINE MONTHS ENDED 31ST DECEMBER,2025

(₹ in Lakhs)

| Sr. No. | Particulars                                                     | Quarter ended |             |             | Nine months ended |             | Year ended |
|---------|-----------------------------------------------------------------|---------------|-------------|-------------|-------------------|-------------|------------|
|         |                                                                 | 31-12-2025    | 30-09-2025  | 31-12-2024  | 31-12-2025        | 31-12-2024  | 31-03-2025 |
|         |                                                                 | (Unaudited)   | (Unaudited) | (Unaudited) | (Unaudited)       | (Unaudited) | (Audited)  |
| 1       | Revenue from operations                                         | -             | -           | -           | -                 | -           | -          |
|         | Other income                                                    | 6.45          | 5.49        | 0.30        | 112.19            | 57.40       | 66.14      |
|         | Total revenue                                                   | 6.45          | 5.49        | 0.30        | 112.19            | 57.40       | 66.14      |
| 2       | Expenses                                                        |               |             |             |                   |             |            |
|         | Employee benefits expense                                       | 0.60          | 0.63        | 3.90        | 4.18              | 10.21       | 13.84      |
|         | Depreciation and amortization expense                           | -             | -           | -           | -                 | 0.04        | 0.07       |
|         | Other expenses                                                  | 1.93          | 3.02        | 2.60        | 12.89             | 8.00        | 11.47      |
|         | Total expenses                                                  | 2.53          | 3.65        | 6.50        | 17.07             | 18.25       | 25.38      |
|         | Profit / (Loss) from ordinary activities before tax             | 3.92          | 1.84        | (6.20)      | 95.12             | 39.15       | 40.76      |
| 3       | Tax expense:                                                    |               |             |             |                   |             |            |
|         | Current tax                                                     | -             | (0.46)      | -           | (22.95)           | -           | -          |
|         | Deferred tax                                                    | -             | -           | -           | -                 | (0.34)      | (0.34)     |
| 4       | Profit/(Loss) from ordinary activities after tax                | 3.92          | 1.38        | (6.20)      | 72.17             | 38.81       | 40.42      |
| 5       | Other Comprehensive Income (OCI)                                |               |             |             |                   |             |            |
|         | <u>Item that will not be reclassified to profit or loss</u>     |               |             |             |                   |             |            |
|         | Gain/(Loss) on recognised on fair valuation of Financial Assets | 2.18          | (1.86)      | -           | 8.87              | (29.78)     | (0.49)     |
|         | Income tax relating to these items                              | 0             | 1.40        | -           | (0.82)            | 7.74        | 0.13       |
|         | Total Other Comprehensive Income (OCI)                          | 2.18          | (0.46)      | -           | 8.05              | (22.04)     | (0.36)     |
|         | Profit/(Loss) for the Period                                    | 6.10          | 0.92        | (6.20)      | 80.22             | 16.77       | 40.06      |
|         | Paid up Equity Share Capital (Face Value of Rs. 10 each)        | 1,397.03      | 1,397.03    | 589.00      | 1,397.03          | 589.00      | 1,397.02   |
| 6       | Earning Per Share ( EPS ) (Not annualised)                      |               |             |             |                   |             |            |
|         | (1) Basic                                                       | 0.03          | 0.01        | (1.00)      | 0.52              | 0.66        | 0.64       |
|         | (2) Diluted                                                     | 0.03          | 0.01        | (1.00)      | 0.52              | 0.66        | 0.64       |

### Notes:

- The Above Financial Results were reviewed by the audit committee of the board on and approved by the Board of Directors of the company at their meeting held on same date. The Statutory auditor have expressed on unmodified opinion. The review report has been filled with stock exchange and is available on the company's website. The Financial results have been prepared in accordance with Ind As notified under the companies (Accounting Standards) Rule 2015.
- Figures for the corresponding quarter ended i.e. 31st March 2025 in the previous year as reported in these financial results are the balancing figures between audited figures in respect of the full financial year and the published year to date figures up to the end of the third quarter of the relevant financial year.
- The Company has single business segment therefore in the context of Ind As 108, disclosure of segment information is not applicable.
- Previous quarter figures have been regrouped /reclassified wherever necessary, to make them comparable.

For and on behalf of the Board

Bacil Pharma Limited

Shah  
Chaitali  
Kalpataru

Digitally signed  
by Shah Chaitali  
Kalpataru  
Date: 2026.02.13  
14:12:00 +05'30'

CHAITALI KALPATARU SHAH

(Director & CFO)

DIN: 11167778




**SARANG SHIVAJIRAO CHAVAN  
AND ASSOCIATES**  
CHARTERED ACCOUNTANTS

CA SARANG CHAVAN  
+91 9974 62 3154  
chavansarang1@gmail.com

Independent Auditor's Review Report on the Quarter Ended 31<sup>st</sup> December, 2025  
Unaudited Financial Results of the Company Pursuant to Regulation 33 of the SEBI  
(Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

To the Board of Directors  
BACIL PHARMA LIMITED

1. We have reviewed the accompanying statement of unaudited financial results of BACIL PHARMA LIMITED (the "Company") for the Quarter ended December, 2025 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "listing Regulations").
2. This Statement, which is the responsibility of Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 ("Ind AS 34"), "Interim Financial Reporting", prescribed under Section 133 of Companies Act, 2013 and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free of material misstatement. A review of the Interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with standards on auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.





# SARANG SHIVAJIRAO CHAVAN AND ASSOCIATES


CHARTERED ACCOUNTANTS

CA SARANG CHAVAN

+91 9974 62 3154

chavansarang1@gmail.com

4. The information and data contained in this report are based solely on the documents, explanations, and representations provided by the management of the entity. We have not independently verified the correctness or completeness of such information and records, and our verification has been limited to the extent of information made available to us during the course of our review.
5. Emphasis of Matter
- (i) The Company has raised funds through preferential allotment. In the absence of adequate documentation and explanations from the management, we are unable to verify their application and end use. Due to lack of complete information and confirmations from management, we are unable to determine whether certain transactions during the quarter are with related parties and if so, whether they are at arm's length. In the absence of sufficient documentation regarding advances/deposits given during the quarter, we are unable to comment on their nature, purpose, recoverability and compliance with applicable provisions.
- (ii) This report is prepared for the exclusive use of the entity and is based on a limited review; it should not be considered as an audit or certification of factual accuracy. We do not assume responsibility to update or revise the report for events occurring after the date of issuance. Nothing contained herein should be construed as an assurance of future performance, compliance, or financial position of the entity. Our responsibility is restricted to the reporting requirements as per the scope of engagement agreed with management and in accordance with the Standards on Quality Control (SQC 1) and relevant Guidance Notes issued by ICAI. This report does not, in any manner, express an audit opinion under the Companies Act, 2013 or under any other statute. The management is responsible for compliance with applicable laws and maintenance of adequate internal controls.








**SARANG SHIVAJIRAO CHAVAN  
AND ASSOCIATES**  
CHARTERED ACCOUNTANTS

CA SARANG CHAVAN  
+91 9974 62 3154  
chavansarang1@gmail.com

- (iii) During the course of our review, it was observed that the Company has not complied with certain statutory requirements under the Goods and Services Tax Act, 2017 and the Income-tax Act, 1961 relating to timely deposit and filing of GST returns and TDS statements. Consequently, interest, penalties, and other liabilities, if any, arising therefrom have not been ascertained and provided for in the books of accounts. In our opinion, this constitutes a non-compliance with statutory provisions which may have a material impact on the financial statements. The above observation is based solely on information and explanations provided by management and our limited review procedures. We have not carried out an audit, and accordingly, we do not express an audit opinion.
- (iv) Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial result prepared in accordance with applicable principles laid down in Indian Accounting Standards 34 "Interim Financial Reporting" ("Ind AS 34") prescribed under section 133 of companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (listing obligations and Disclosure Requirements) Regulations, 2015 read with the Circular, Including the Manner in which it is to be disclosed or that it contains any material misstatement.
- (v) We have not been provided any data regarding debtors and creditors confirmation from management however we have asked them to provide emails of debtors and creditors for the purpose of external balance confirmation via email and hence for time being we have relied on management declaration and representation made by them.





**SARANG SHIVAJIRAO CHAVAN  
AND ASSOCIATES**  
CHARTERED ACCOUNTANTS

CA SARANG CHAVAN  
+91 9974 62 3154  
chavansarang1@gmail.com

- (vi) With regard to investments and deposits and loans and advances made in books of accounts, we have not been provided any data from management, however we have asked them to provide emails of concerned person to whom investments, deposits and loans and advances has been made for the purpose of external balance confirmation via email and hence for time being we have relied on management declaration and representation made by them.
- (vii) We do not express an opinion on the Statement of the Company. Because of the significance of the matters described in the Basis for Disclaimer of Opinion section of our review report, we have not been able to obtain sufficient and appropriate audit evidence to provide a basis for our opinion on the Statement.

FOR  
SARANG SHIVAJIRAO CHAVAN AND ASSOCIATES  
CHARTERED ACCOUNTANTS  
FRN: 159649W

CA SARANG CHAVAN  
(PROPRIETOR)  
M.NO.142576  
UDIN: 26142576DQIWIP7118  
Date: 13/02/2026  
Place: Ahmedabad

